In Vitro Effect Study of Interleukin-2 Muteins on Regulatory T Cells of Patients With Different Autoimmune, Allo-immune or Inflammatory Diseases

Inclusion Criteria: * Inclusion criteria common to all patients in different departments: * Age18 years * Affiliated to social security or entitled to * Patient who has been informed of the study and has signed a free and informed consent Inclusion criteria specific by department: Inclusion criteria for Clinical Hematology Department: * Patient with GVHD following allogeneic hematopoietic stem cell transplantation (HSC) * Or with acquired bone marrow suppression * Lymphocytosis \> 0.5 G/L Inclusion criteria for Nephrology and Transplantation department: \- Patient with systemic lupus erythematosus (ACR classification criteria) Inclusion criteria for Neurology department: \- Patient with multiple sclerosis (criteria of Mc Donald 2017) Inclusion criteria for Rheumatology Department: \- Patient with rheumatoid arthritis (ACR classification criteria) Inclusion criteria for Internal Medicine-Endocrinology Department: \- Patient with Basedow disease, Hashimoto's thyroiditis Inclusion criteria for Dermatology Department: \- Patient with vitiligo or alopecia areata or atopic dermatitis Exclusion Criteria: Non-inclusion criteria common to all patients: * Patient under guardianship, curatorship or judicial protection * Pregnant, parturient or breastfeeding woman * Patient deprived of liberty * Patient hospitalized without consent * Patient admitted to a health or social institution for purposes other than research * Minor patient * Adult patient unable to express consent * Refusal to participate * Patient on AME Non-inclusion criteria specific by department: Non-inclusion criteria for Clinical Hematology Department: * Ongoing treatment with high doses (\>1 mg/kg/d) of systemic corticosteroid therapy * Ongoing treatment with JAK inhibitors Non-inclusion criteria for Nephrology and Transplantation Department: * Ongoing treatment with doses \>10 mg/d Prednisone * Ongoing treatment with Cellcept, Endoxan, Imurel, Belimumab, Anti-CD20, Methotrexate * Ongoing treatment with JAK inhibitors Non-inclusion criteria for Neurology Department: * Treatment with systemic corticosteroid therapy, Fingolimod or Teriflunomide * Ongoing treatment with JAK inhibitors * Lymphocytosis \< 0.5 G/L Non-inclusion criteria for Rheumatology Department: * Ongoing treatment with doses \>15 mg/d Prednisone * Treatment with Rituximab or Tocilizumab * Ongoing treatment with JAK inhibitors * Lymphocytosis \< 0.5 G/L Non-inclusion criteria for Internal Medicine - Endocrinology Department: * Ongoing immunosuppressive therapy * Ongoing treatment with JAK inhibitors Non-inclusion criteria for Dermatology Department: * Ongoing treatment with Methotrexate * Ongoing treatment with JAK inhibitors * Ongoing treatment with doses \>10 mg/d prednisone